Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Classement en actions #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Prix de l'action
$0.15
Capitalisation boursière
$4.96M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
CA
Échange Intellipharmaceutics International Inc. (IPCIF)

Catégorie

Bénéfices pour Intellipharmaceutics International Inc. (IPCIF)
Bénéfices en Aug 2023 TTM : $-3.17M
Selon les derniers rapports financiers de Intellipharmaceutics International Inc., les bénéfices actuels de l'entreprise sont de $-3.17M. En 2021, l'entreprise a réalisé un bénéfice de $-2.89M, une augmentation par rapport à celui de 2020 qui était de $-5.26M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Intellipharmaceutics International Inc. de 1999 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-3.17M 9.75%
2022 $-2.89M 0.00%
2021 $-2.89M -45.11%
2020 $-5.26M 56.62%
2019 $-3.36M -75.57%
2018 $-13.75M 55.21%
2017 $-8.86M -12.68%
2016 $-10.14M 36.40%
2015 $-7.44M 92.83%
2014 $-3.86M -66.45%
2013 $-11.50M 135.54%
2012 $-4.88M 95.22%
2011 $-2.50M -56.34%
2010 $-5.73M -55.76%
2008 $-12.94M -56.95%
2007 $-30.07M -49.08%
2006 $-59.05M -25.61%
2005 $-79.37M 13.77%
2004 $-69.77M 173.92%
2003 $-25.47M 104.32%
2002 $-12.47M 36.27%
2001 $-9.15M 41.00%
2000 $-6.49M 0.00%
1999 0.00 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$20.46B -645,746.69%
DK
$4.64B -146,643.73%
US
$5.23B -165,185.78%
US
$2.14B -67,567.64%
BE
$1.45B -45,897.45%
NL